Pancreatic Cancer Research

ResearcherLeiden University Medical CenterActive in the last 2 years

Jesse V. Groen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2438-4665; OpenAlex author ID A5086117338. Sources: OpenAlex.

Their work

Papers
19 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
79
Papers, trials and grants by year

2018: 1 paper · 2019: 2 papers · 2020: 5 papers · 2021: 4 papers · 2022: 4 papers · 2023: 2 papers · 2024: none · 2025: 1 paper

Papers 19

  1. Tumor gene expression is associated with venous thromboembolism in patients with ductal pancreatic adenocarcinoma. Co-author DOI 10.1016/j.thromres.2024.109240↗
  2. Practice variation in venous resection during pancreatoduodenectomy for pancreatic cancer: A nationwide cohort study. Co-author DOI 10.1016/j.surg.2023.06.012↗
  3. Intraoperative Ultrasound During Surgical Exploration in Patients with Pancreatic Cancer and Vascular Involvement (ULTRAPANC): A Prospective Multicenter Study. Co-author DOI 10.1245/s10434-023-13112-3↗
  4. Author response to: Venous wedge and segment resection during pancreatoduodenectomy for pancreatic cancer: impact on short- and long-term outcomes in a nationw… Co-author DOI 10.1093/bjs/znac060↗
  5. Impact of classical and basal-like molecular subtypes on overall survival in resected pancreatic cancer in the SPACIOUS-2 multicentre study. Co-author DOI 10.1093/bjs/znac272↗
  6. External Validity of the Multicenter Randomized PREOPANC Trial on Neoadjuvant Chemoradiotherapy in Pancreatic Cancer: Outcome of Eligible but Nonrandomized Pat… Co-author DOI 10.1097/sla.0000000000004364↗
  7. High Systemic Immune Inflammation Index Is Associated With Low Skeletal Muscle Quantity in Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2022.827755↗
  8. Incidence, timing and risk factors of venous thromboembolic events in patients with pancreatic cancer. First author DOI 10.1016/j.thromres.2021.08.002↗
  9. Venous wedge and segment resection during pancreatoduodenectomy for pancreatic cancer: impact on short- and long-term outcomes in a nationwide cohort analysis. Co-author DOI 10.1093/bjs/znab345↗
  10. Resection of the Portal-Superior Mesenteric Vein in Pancreatic Cancer: Pathological Assessment and Recurrence Patterns. Co-author DOI 10.1097/mpa.0000000000001897↗
  11. An Immunohistochemical Evaluation of Tumor-Associated Glycans and Mucins as Targets for Molecular Imaging of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13225777↗
  12. International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer. Co-author DOI 10.1016/j.ejso.2019.12.023↗
  13. Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis. First author DOI 10.1080/1354750x.2020.1725786↗
  14. Treatment and Survival of Elderly Patients with Stage I-II Pancreatic Cancer: A Report of the EURECCA Pancreas Consortium. First author DOI 10.1245/s10434-020-08539-x↗
  15. ASO Author Reflections: Can Utilization of Cancer Registry Data Contribute to Solving the Lack of Evidence for Older Pancreatic Cancer Patients? Co-author DOI 10.1245/s10434-020-08611-6↗
  16. Stage-Specific Value of Carbohydrate Antigen 19-9 and Carcinoembryonic Antigen Serum Levels on Survival and Recurrence in Pancreatic Cancer: A Single Center St… First author DOI 10.3390/cancers12102970↗
  17. Impact of resection margin status on recurrence and survival in pancreatic cancer surgery. First author DOI 10.1002/bjs.11115↗
  18. Author response to: Resection margin status in pancreatic cancer surgery: is it really less important than the N status? Co-author DOI 10.1002/bjs.11355↗
  19. Differences in Treatment and Outcome of Pancreatic Adenocarcinoma Stage I and II in the EURECCA Pancreas Consortium. Co-author DOI 10.1245/s10434-018-6705-1↗

Closest collaborators

The 25 strongest of 79 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. J. Sven D. Mieog · 17 shared papers, 2018–2025 · strength 2.19
  2. Bert A. Bonsing · 14 shared papers, 2018–2025 · strength 1.67
  3. Marc G. Besselink · 9 shared papers, 2020–2025 · strength 1.09
  4. Alexander L. Vahrmeijer · 7 shared papers, 2019–2023 · strength 0.84
  5. Casper H.J. van Eijck · 6 shared papers, 2020–2023 · strength 0.68
  6. Izaak Quintus Molenaar · 5 shared papers, 2021–2025 · strength 0.66
  7. Bas Groot Koerkamp · 6 shared papers, 2020–2023 · strength 0.64
  8. Nynke Michiels · 4 shared papers, 2021–2023 · strength 0.63
  9. Ignace H. J. T. de Hingh · 4 shared papers, 2021–2023 · strength 0.50
  10. Joanne Verheij · 3 shared papers, 2021–2025 · strength 0.42
  11. Martin N.J.M. Wasser · 3 shared papers, 2021–2023 · strength 0.37
  12. Labrinus van Manen · 3 shared papers, 2020–2021 · strength 0.36
  13. Hjalmar C. van Santvoort · 3 shared papers, 2021–2023 · strength 0.36
  14. Rutger‐Jan Swijnenburg · 3 shared papers, 2019–2020 · strength 0.35
  15. Randa G. Hanna-Sawires · 2 shared papers, 2021–2025 · strength 0.31
  16. Frederike Dijk · 2 shared papers, 2022–2025 · strength 0.30
  17. Lodewijk A.A. Brosens · 2 shared papers, 2022–2025 · strength 0.30
  18. Maarten F. Bijlsma · 2 shared papers, 2022–2025 · strength 0.30
  19. Stijn R. van Roessel · 3 shared papers, 2020–2021 · strength 0.28
  20. Mustafa Suker · 2 shared papers, 2022 · strength 0.26
  21. Willemieke S. F. J. Tummers · 2 shared papers, 2019 · strength 0.23
  22. Vincent B. Nieuwenhuijs · 2 shared papers, 2021–2023 · strength 0.22
  23. Vincent Erwin de Meijer · 2 shared papers, 2021–2023 · strength 0.22
  24. Babs M. Zonderhuis · 2 shared papers, 2021–2023 · strength 0.22
  25. Judith de Vos‐Geelen · 2 shared papers, 2021–2023 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.